These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31016561)

  • 1. Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis.
    Lee H; Schneider Y; Lichtenstein GR
    Dig Dis Sci; 2019 May; 64(5):1138-1141. PubMed ID: 31016561
    [No Abstract]   [Full Text] [Related]  

  • 2. Giant Cell [Granulomatous] Gastritis in Left-sided Paediatric Ulcerative Colitis.
    Alfaro-Cruz L; Schady D; Kellermayer R
    J Crohns Colitis; 2019 Mar; 13(3):396-397. PubMed ID: 30351395
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term infliximab therapy is needed for sustained steroid-free remission in patients with ulcerative colitis.
    Le Roy F; Siproudhis L; Bretagne JF; Bouguen G
    Dig Liver Dis; 2016 Feb; 48(2):208-9. PubMed ID: 26614643
    [No Abstract]   [Full Text] [Related]  

  • 4. What is causing this patient's multiple skin abscesses?
    Little K
    JAAPA; 2018 Nov; 31(11):54-55. PubMed ID: 30358682
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporin for severe ulcerative colitis: a user's guide.
    Kornbluth A; Present DH; Lichtiger S; Hanauer S
    Am J Gastroenterol; 1997 Sep; 92(9):1424-8. PubMed ID: 9317057
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
    Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
    J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab as Rescue Treatment in Sweet's Syndrome Related to Corticodependent Ulcerative Colitis.
    Moreno Márquez C; Maldonado Pérez B; Castro Laria L
    J Crohns Colitis; 2018 May; 12(6):755-756. PubMed ID: 29474532
    [No Abstract]   [Full Text] [Related]  

  • 8. Lower Dose Infliximab for Ulcerative Colitis: How Low Can We Go and How Much Can be Saved?
    Christophi GP; Ciorba MA
    J Clin Gastroenterol; 2015 Aug; 49(7):539-40. PubMed ID: 26057322
    [No Abstract]   [Full Text] [Related]  

  • 9. The Effect of Biosimilars [Inflectra®] in the Management of Acute Severe Ulcerative Colitis.
    Harkin G; Keogh Á; Slattery E
    J Crohns Colitis; 2017 Oct; 11(11):1400-1401. PubMed ID: 28444254
    [No Abstract]   [Full Text] [Related]  

  • 10. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis.
    Jiang XL; Cui HF; Gao J; Fan H
    J Clin Gastroenterol; 2015 Aug; 49(7):582-8. PubMed ID: 25844841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of severe attack of ulcerative colitis].
    Tysk C; Almer S; Andersson MV; Befrits R; Hertervig E; Kilander A; Lindgren S; Suhr O
    Lakartidningen; 2009 Nov 4-12; 106(45):2994-8. PubMed ID: 19998825
    [No Abstract]   [Full Text] [Related]  

  • 14. Ulcerative colitis: responding to the challenges.
    Achkar JP
    Cleve Clin J Med; 2007 Sep; 74(9):657-60. PubMed ID: 17879519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients.
    Pérez-Pitarch A; Ferriols-Lisart R; Alós-Almiñana M; Mínguez-Pérez M
    Rev Esp Enferm Dig; 2015 Mar; 107(3):137-42. PubMed ID: 25733037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe Henoch-Schönlein purpura complicating infliximab therapy for ulcerative colitis.
    Laresche C; Locatelli F; Biver-Dalle C; Nachury M; Heyd B; Koch S; Aubin F
    Cutis; 2017 Jan; 99(1):E20-E22. PubMed ID: 28207014
    [No Abstract]   [Full Text] [Related]  

  • 17. Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis.
    Clemmensen K; Akrawi N; Stawowy M
    Scand J Gastroenterol; 2015; 50(12):1508-11. PubMed ID: 26133362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.
    Chiba M; Kimura K
    J Gastroenterol; 2024 Jul; 59(7):641-642. PubMed ID: 38702533
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab efficacy in pediatric ulcerative colitis.
    Eidelwein AP; Cuffari C; Abadom V; Oliva-Hemker M
    Inflamm Bowel Dis; 2005 Mar; 11(3):213-8. PubMed ID: 15735427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrochemiluminescence immunoassay method underestimates cortisol suppression in ulcerative colitis patients treated with oral prednisone.
    Manguso F; Bennato R; Lombardi G; Viola A; Riccio E; Cipolletta L
    World J Gastroenterol; 2014 Aug; 20(31):10895-9. PubMed ID: 25152591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.